Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

1.

Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Eap CB, Buclin T, Baumann P.

Clin Pharmacokinet. 2002;41(14):1153-93. Review.

PMID:
12405865
[PubMed - indexed for MEDLINE]
2.

[Methadone: from pharmacokinetic profile to clinical pharmacology].

Vazquez V, Gury C, Laqueille X.

Encephale. 2006 Jul-Aug;32(4 Pt 1):478-86. Review. French.

PMID:
17099560
[PubMed - indexed for MEDLINE]
3.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
[PubMed - indexed for MEDLINE]
4.

High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.

Säwe J.

Clin Pharmacokinet. 1986 Mar-Apr;11(2):87-106. Review.

PMID:
3514045
[PubMed - indexed for MEDLINE]
5.

Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients.

Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F.

Br J Clin Pharmacol. 2000 Nov;50(5):427-40.

PMID:
11069437
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment.

Eap CB, Bourquin M, Martin J, Spagnoli J, Livoti S, Powell K, Baumann P, Déglon J.

Drug Alcohol Depend. 2000 Dec 22;61(1):47-54.

PMID:
11064183
[PubMed - indexed for MEDLINE]
7.

Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.

Crettol S, Déglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hämmig R, Monnat M, Hüttemann H, Baumann P, Eap CB.

Clin Pharmacol Ther. 2005 Dec;78(6):593-604.

PMID:
16338275
[PubMed - indexed for MEDLINE]
8.

Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.

Foster DJ, Somogyi AA, White JM, Bochner F.

Br J Clin Pharmacol. 2004 Jun;57(6):742-55.

PMID:
15151520
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate.

Boulton DW, Arnaud P, DeVane CL.

Clin Pharmacol Ther. 2001 Jul;70(1):48-57.

PMID:
11452244
[PubMed - indexed for MEDLINE]
10.

Interindividual variability of methadone response: impact of genetic polymorphism.

Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S.

Mol Diagn Ther. 2008;12(2):109-24. Review.

PMID:
18422375
[PubMed - indexed for MEDLINE]
11.

Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses.

Shinderman M, Maxwell S, Brawand-Amey M, Golay KP, Baumann P, Eap CB.

Drug Alcohol Depend. 2003 Mar 1;69(2):205-11.

PMID:
12609702
[PubMed - indexed for MEDLINE]
12.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
[PubMed - indexed for MEDLINE]
13.

ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.

Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, Eap CB.

Clin Pharmacol Ther. 2006 Dec;80(6):668-81.

PMID:
17178267
[PubMed - indexed for MEDLINE]
14.

Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients.

Uehlinger C, Crettol S, Chassot P, Brocard M, Koeb L, Brawand-Amey M, Eap CB.

J Clin Psychopharmacol. 2007 Jun;27(3):273-8.

PMID:
17502774
[PubMed - indexed for MEDLINE]
15.

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

Foster RH, Goa KL.

CNS Drugs. 1997 Aug;8(2):163-88. doi: 10.2165/00023210-199708020-00010.

PMID:
23338224
[PubMed]
16.

Clinical pharmacokinetics of nisoldipine coat-core.

Heinig R.

Clin Pharmacokinet. 1998 Sep;35(3):191-208. Review. Erratum in: Clin Pharmacokinet 1998 Nov;35(5):390.

PMID:
9784933
[PubMed - indexed for MEDLINE]
17.

When "enough" is not enough: new perspectives on optimal methadone maintenance dose.

Leavitt SB, Shinderman M, Maxwell S, Eap CB, Paris P.

Mt Sinai J Med. 2000 Oct-Nov;67(5-6):404-11. Review.

PMID:
11064491
[PubMed - indexed for MEDLINE]
18.

Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.

Lötsch J, Skarke C, Wieting J, Oertel BG, Schmidt H, Brockmöller J, Geisslinger G.

Clin Pharmacol Ther. 2006 Jan;79(1):72-89.

PMID:
16413243
[PubMed - indexed for MEDLINE]
19.

Clinical pharmacokinetics of mirtazapine.

Timmer CJ, Sitsen JM, Delbressine LP.

Clin Pharmacokinet. 2000 Jun;38(6):461-74. Review.

PMID:
10885584
[PubMed - indexed for MEDLINE]
20.

Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment.

Shiran MR, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT, Rostami-Hodjegan A.

J Clin Psychopharmacol. 2012 Oct;32(5):666-71. doi: 10.1097/JCP.0b013e3182664ecd.

PMID:
22926601
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk